Semaglutide

Nombre químico: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18-diacid-gamma-Glu-OEG-OEG)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH // Sinónimos: (Aib8,Lys(C18-diacid-gamma-Glu-OEG-OEG)26,Arg34)-GLP-1 (7-37), One letter Code: H-Aib-EGTFTSDVSSYLEGQAAK(C18-diacid-gamma-Glu-OEG-OEG)EFIAWLVRGRG

Nº Artículo:LS-4040
Nº CAS:910463-68-2
Fórmula:C₁₈₇H₂₉₁N₄₅O₅₉
Masa molecular:4113,64 g/mol
Pureza:min. 99.0%, no single impurity

Starting at A petición

Grouped product items
Cantidad	Unidad de venta	Precio	Unidad de almacenamiento de stock (SKU)
A petición	A petición	A petición	LS-4040.0000
Hoja de seguridad

Inquiry

Skip to the end of the images gallery

Skip to the beginning of the images gallery

description

A GLP-1 analogue, which is acylated with a fatty acid residue, stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. The long alkyl side chain induces interaction with plasma albumin resulting in extended half-life.

This product is solely provided for research and uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Iris Biotech against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

references

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes; S. P. Marso, S. C. Bain, A. Consoli, F. G. Eliaschewitz, E. Jodar, L. A. Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. L. Warren, V. Woo, O. Hansen, A. G. Holst, J. Pettersson, T. Vilsboll and S.-. Investigators; N Engl J Med 2016; 375: 1834-1844. https://doi.org/10.1056/NEJMoa1607141

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide; J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L. B. Knudsen, J. McGuire, D. B. Steensgaard, H. M. Strauss, D. X. Gram, S. M. Knudsen, F. S. Nielsen, P. Thygesen, S. Reedtz-Runge and T. Kruse; Journal of medicinal chemistry 2015; 58: 7370-7380. https://doi.org/10.1021/acs.jmedchem.5b00726

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates; C. F. Gotfredsen, A. M. Molck, I. Thorup, N. C. Nyborg, Z. Salanti, L. B. Knudsen and M. O. Larsen; Diabetes 2014; 63: 2486-97. https://doi.org/10.2337/db13-1087